TABLE 1.

Changes in composite symptom scores, peak eosinophil counts, and EoE endoscopic reference scores in all included patients and stratified by those on dupilumab for 0–12, 12–24, and greater than 24 weeks.

Characteristics, median (Q1 to Q3)	All included patients (n = 79)	Patients on dupilumab for 0–12 weeks (n = 12)	Patients on dupilumab for 12–24 weeks (n = 38)	Patients on dupilumab for longer than 24 weeks (n = 29)	p‐value
Change in composite symptoms scores	−5.0 (−6.0 to −3.0)	−5.5 (−6.0 to −4.0)	−5.0 (−6.0 to −3.8)	−3.0 (−6.0 to −2.0)	0.1350
Changes in peak eosinophil count (eos/hpf)	−33.0 (−54.0 to −18.0)	−24.5 (−54.3 to −5.5)	−35.0 (−49.3 to −24.0)	−45.0 (−78.0 to −25.0)	0.0746
Changes in EoE endoscopic reference scores	−1.0 (−4.0 to 0.0)	−2.0 (−4.0 to 0.50)	−1.0 (−3.0 to 0.0)	−1.0 (−2.0 to −0.25)	0.8771

Note: Change in EoE endoscopic reference scores is only available for 15 patients. p value corresponds to Kruskal‐Wallis test comparing patients on dupilumab for 0–12, 12–24, and greater than 24 weeks.